Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.

Saved in:
Bibliographic Details
Title: Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.
Authors: Heitner SB; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR. Electronic address: heitner@ohsu.edu., Minnier J; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR; OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR., Naher A; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR., Van Woerkom RC; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR., Ritts A; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR., Ferencik M; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR., Broberg C; Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR., Medvedova E; OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR., Silbermann R; OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR., Scott EC; OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, OR.
Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2018 Dec; Vol. 18 (12), pp. 796-802. Date of Electronic Publication: 2018 Aug 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first